vs

Side-by-side financial comparison of Foghorn Therapeutics Inc. (FHTX) and Linde plc (LIN). Click either name above to swap in a different company.

Foghorn Therapeutics Inc. is the larger business by last-quarter revenue ($9.2M vs $8.8M, roughly 1.1× Linde plc). On growth, Foghorn Therapeutics Inc. posted the faster year-over-year revenue change (223.8% vs 8.2%). Over the past eight quarters, Foghorn Therapeutics Inc.'s revenue compounded faster (35.3% CAGR vs -96.7%).

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing novel therapies targeting the chromatin regulatory system to treat various types of cancer and other severe diseases. It advances a diverse pipeline of targeted drug candidates, conducting internal R&D and strategic partnerships to serve global patient populations.

Linde is a global multinational chemical company and the world's largest industrial gas supplier by market share and revenue. Founded by German scientist and engineer Carl von Linde in 1879 in Wiesbaden, Germany, the company is now headquartered in Woking, United Kingdom, and registered in Ireland as Linde plc. Linde plc was formed in 2018 through the merger of Linde AG and Praxair, which was founded in 1907 in the United States as Linde Air Products Company.

FHTX vs LIN — Head-to-Head

Bigger by revenue
FHTX
FHTX
1.1× larger
FHTX
$9.2M
$8.8M
LIN
Growing faster (revenue YoY)
FHTX
FHTX
+215.5% gap
FHTX
223.8%
8.2%
LIN
Faster 2-yr revenue CAGR
FHTX
FHTX
Annualised
FHTX
35.3%
-96.7%
LIN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
FHTX
FHTX
LIN
LIN
Revenue
$9.2M
$8.8M
Net Profit
$-21.7M
Gross Margin
48.5%
Operating Margin
-258.2%
27.8%
Net Margin
-234.3%
Revenue YoY
223.8%
8.2%
Net Profit YoY
-11.1%
EPS (diluted)
$-0.35
$3.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FHTX
FHTX
LIN
LIN
Q1 26
$8.8M
Q4 25
$9.2M
$8.8B
Q3 25
$8.2M
$8.6B
Q2 25
$7.6M
$8.5B
Q1 25
$6.0M
$8.1B
Q4 24
$2.9M
$8.3B
Q3 24
$7.8M
$8.4B
Q2 24
$6.9M
$8.3B
Net Profit
FHTX
FHTX
LIN
LIN
Q1 26
Q4 25
$-21.7M
$1.5B
Q3 25
$-15.8M
$1.9B
Q2 25
$-17.9M
$1.8B
Q1 25
$-18.8M
$1.7B
Q4 24
$-19.5M
$1.7B
Q3 24
$-19.1M
$1.6B
Q2 24
$-23.0M
$1.7B
Gross Margin
FHTX
FHTX
LIN
LIN
Q1 26
48.5%
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Operating Margin
FHTX
FHTX
LIN
LIN
Q1 26
27.8%
Q4 25
-258.2%
23.0%
Q3 25
-226.9%
27.5%
Q2 25
-279.2%
27.7%
Q1 25
-385.0%
26.9%
Q4 24
-840.5%
27.4%
Q3 24
-305.5%
25.0%
Q2 24
-386.6%
26.4%
Net Margin
FHTX
FHTX
LIN
LIN
Q1 26
Q4 25
-234.3%
17.5%
Q3 25
-194.4%
22.4%
Q2 25
-237.3%
20.8%
Q1 25
-316.4%
20.6%
Q4 24
-682.9%
20.8%
Q3 24
-244.9%
18.5%
Q2 24
-333.6%
20.1%
EPS (diluted)
FHTX
FHTX
LIN
LIN
Q1 26
$3.98
Q4 25
$-0.35
$3.28
Q3 25
$-0.25
$4.09
Q2 25
$-0.28
$3.73
Q1 25
$-0.30
$3.51
Q4 24
$-0.23
$3.61
Q3 24
$-0.31
$3.22
Q2 24
$-0.45
$3.44

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FHTX
FHTX
LIN
LIN
Cash + ST InvestmentsLiquidity on hand
$80.9M
$4.0M
Total DebtLower is stronger
$24.7M
Stockholders' EquityBook value
$-108.5M
$40.1M
Total Assets
$198.1M
$86.3M
Debt / EquityLower = less leverage
0.62×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FHTX
FHTX
LIN
LIN
Q1 26
$4.0M
Q4 25
$80.9M
$5.1B
Q3 25
$89.3M
$4.5B
Q2 25
$72.6M
$4.8B
Q1 25
$61.0M
$5.3B
Q4 24
$55.5M
$4.8B
Q3 24
$57.7M
$5.2B
Q2 24
$138.9M
$4.6B
Total Debt
FHTX
FHTX
LIN
LIN
Q1 26
$24.7M
Q4 25
$20.7B
Q3 25
$18.6B
Q2 25
$19.7B
Q1 25
$17.6B
Q4 24
$15.3B
Q3 24
$17.5B
Q2 24
$16.9B
Stockholders' Equity
FHTX
FHTX
LIN
LIN
Q1 26
$40.1M
Q4 25
$-108.5M
$38.2B
Q3 25
$-89.7M
$38.6B
Q2 25
$-76.7M
$38.5B
Q1 25
$-61.7M
$38.0B
Q4 24
$-45.5M
$38.1B
Q3 24
$-28.3M
$39.2B
Q2 24
$-14.3M
$38.2B
Total Assets
FHTX
FHTX
LIN
LIN
Q1 26
$86.3M
Q4 25
$198.1M
$86.8B
Q3 25
$205.0M
$86.0B
Q2 25
$226.2M
$86.1B
Q1 25
$258.7M
$82.7B
Q4 24
$284.0M
$80.1B
Q3 24
$308.4M
$82.5B
Q2 24
$328.6M
$80.2B
Debt / Equity
FHTX
FHTX
LIN
LIN
Q1 26
0.62×
Q4 25
0.54×
Q3 25
0.48×
Q2 25
0.51×
Q1 25
0.46×
Q4 24
0.40×
Q3 24
0.45×
Q2 24
0.44×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FHTX
FHTX
LIN
LIN
Operating Cash FlowLast quarter
$-22.3M
Free Cash FlowOCF − Capex
$898.0K
FCF MarginFCF / Revenue
10.2%
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$4.2B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FHTX
FHTX
LIN
LIN
Q1 26
Q4 25
$-22.3M
$3.0B
Q3 25
$-18.9M
$2.9B
Q2 25
$-21.0M
$2.2B
Q1 25
$-24.0M
$2.2B
Q4 24
$-24.5M
$2.8B
Q3 24
$-21.0M
$2.7B
Q2 24
$-25.5M
$1.9B
Free Cash Flow
FHTX
FHTX
LIN
LIN
Q1 26
$898.0K
Q4 25
$1.6B
Q3 25
$1.7B
Q2 25
$-21.0M
$954.0M
Q1 25
$-24.0M
$891.0M
Q4 24
$-25.0M
$1.6B
Q3 24
$-21.3M
$1.7B
Q2 24
$-25.6M
$796.0M
FCF Margin
FHTX
FHTX
LIN
LIN
Q1 26
10.2%
Q4 25
17.9%
Q3 25
19.4%
Q2 25
-278.2%
11.2%
Q1 25
-403.2%
11.0%
Q4 24
-875.3%
18.8%
Q3 24
-273.0%
19.9%
Q2 24
-371.0%
9.6%
Capex Intensity
FHTX
FHTX
LIN
LIN
Q1 26
Q4 25
0.0%
16.6%
Q3 25
0.0%
14.8%
Q2 25
0.3%
14.8%
Q1 25
0.5%
15.7%
Q4 24
16.8%
15.1%
Q3 24
4.0%
12.8%
Q2 24
0.2%
13.7%
Cash Conversion
FHTX
FHTX
LIN
LIN
Q1 26
Q4 25
1.98×
Q3 25
1.53×
Q2 25
1.25×
Q1 25
1.29×
Q4 24
1.63×
Q3 24
1.76×
Q2 24
1.16×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons